Trial Profile

Efficacy and tolerability of everolimus [Xience V] vs sirolimus [Cypher] drug eluting stents for the prevention of coronary artery restenosis and cardiovascular events in patients undergoing percutaneous coronary interventions: APPENDIX-AMI

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Aug 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Sirolimus (Primary)
Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Acronyms APPENDIX-AMI

13 Dec 2011 New source identified and integrated (Netherlands Trial Register).
13 Dec 2011 Planned end date (Jun 2012) added as reported by Netherlands Trial Register record.
13 Dec 2011 Planned number of patients 2000, lead trial centre, actual initiation date 1 Dec 2007 added as reported by Netherlands Trial Register record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com